2025 Q4 -tulosraportti
59 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenAnd to my Danish friends, in Norway we have a company called Kitron, it produces among other things components for the defense industry, among other things for Kongsberggruppen, I am absolutely sure that Kitron will at least double within one to two years as all of Europe/the world will now rearm the defense industry. But remember that such investments come from the public sector and often take some time, that's why I say one to two years..
·22 min sittenDeeply overvalued. It is set to fall significantly.·18 min sittenPlease come over to the forum on stocks with great growth potential, I like to hear others' opinions when they are opposite of mine. As an investor, I must indeed look at all sides of a matter... Why do you think it's falling?
·2 t sittenThat's a huge piece of news from England. Strange that it doesn't create more positive sentiment. One million people are not just offered but directly encouraged by the public sector to take Wegovy. A price agreement with subsidies has been made. The group will presumably have it for life, and the group will only get bigger. That should be at least 20 billion annually into the coffers. Huge news. And it will undoubtedly set a precedent in other countries.
·36 min sittenThis is probably somewhat in the middle. The case for Novo Nordisk is still strong in the long term, but much of the optimism surrounding obesity treatment has already been priced into the stock. NHS is positive, but hardly a gamechanger on its own. I have personally been badly burned by this stock; it is actually my biggest loss. Nevertheless, I am still holding it. In a 5 to 10-year perspective, I believe growth will come, but it won't be a straight line up. Competition, price pressure, and regulatory conditions will play a role along the way. Whether there's a buying opportunity now depends mostly on time horizon and patience. I have it as part of my core portfolio, but I have more faith in other stocks this current year.·32 min sittenSame here actually, have almost 50 percent loss, but can afford to stay invested for a long time if necessary, as long as there's hope for improvement, you know. Then I'll wait and see a bit, but if we drop down towards 200 then I'll add a bit more...thanks for the reply:-)
·3 t sittenOver Easter, I have conducted some complex analyses of both micro- and macrotrends and concluded that Novo will hit price 1000 around mid-2031.
·1 t sittenA good Easter lunch with friends, with lots of snaps beer & port wine, is always the ideal setup for preparing a sharp credible analysis. Novo definitely has the potential to become this year's winner on the sluggish C25. Going All Inn next week and buying 5 Novo shares. Done with gambling....
·4 t sittenInteresting to know how the weight loss percentage on the Wegovy pill is without fasting? If it without fasting matches Orforglipron, then the Wegovy pill has more possibilities.·2 t sittenYes, but I would still argue that if the one pill is almost 5% better, it will not be seen as a problem to take it in the morning. I myself take some medications that I can take in the morning, and it has just become a fixed routine, actually very good because then I don't have to wonder if I've taken the pill later in the day. So I feel completely sure that this will be the preferred pill, and will actually buy myself a bit more if we dip down towards 200.. Even though, isolatedly speaking, I shouldn't really have invested more, but this is a case where I see it as justifiable to invest a bit more than planned given that the stock has fallen so much.. I am actually a bit surprised by how short-sighted many stock traders are.. But these are just my thoughts, Have a continued good Easter, folks:-)
·5 t sittenNovo has in the first 3 months sold Wegovy pills for approx 1.5 billion kr. April will approx add 1 billion on top. Are there any expectations for the sales?
·3 t sittenIs that your own assessment since Novo has not announced anything?
·3 t sitten · MuokattuLast Friday, approximately 742,000 prescriptions were sold, and with all sales channels, the number is estimated to be approximately double. The 2 smallest doses cost almost 1,000 kr and approximately double for the 2 largest doses. So if the numbers are correct, then 1.5 billion in Q1 is underestimated. If 50/50 of the doses have been sold, the number is approximately 2.2 billion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
59 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenAnd to my Danish friends, in Norway we have a company called Kitron, it produces among other things components for the defense industry, among other things for Kongsberggruppen, I am absolutely sure that Kitron will at least double within one to two years as all of Europe/the world will now rearm the defense industry. But remember that such investments come from the public sector and often take some time, that's why I say one to two years..·22 min sittenDeeply overvalued. It is set to fall significantly.·18 min sittenPlease come over to the forum on stocks with great growth potential, I like to hear others' opinions when they are opposite of mine. As an investor, I must indeed look at all sides of a matter... Why do you think it's falling?
- ·2 t sittenThat's a huge piece of news from England. Strange that it doesn't create more positive sentiment. One million people are not just offered but directly encouraged by the public sector to take Wegovy. A price agreement with subsidies has been made. The group will presumably have it for life, and the group will only get bigger. That should be at least 20 billion annually into the coffers. Huge news. And it will undoubtedly set a precedent in other countries.·36 min sittenThis is probably somewhat in the middle. The case for Novo Nordisk is still strong in the long term, but much of the optimism surrounding obesity treatment has already been priced into the stock. NHS is positive, but hardly a gamechanger on its own. I have personally been badly burned by this stock; it is actually my biggest loss. Nevertheless, I am still holding it. In a 5 to 10-year perspective, I believe growth will come, but it won't be a straight line up. Competition, price pressure, and regulatory conditions will play a role along the way. Whether there's a buying opportunity now depends mostly on time horizon and patience. I have it as part of my core portfolio, but I have more faith in other stocks this current year.·32 min sittenSame here actually, have almost 50 percent loss, but can afford to stay invested for a long time if necessary, as long as there's hope for improvement, you know. Then I'll wait and see a bit, but if we drop down towards 200 then I'll add a bit more...thanks for the reply:-)
- ·3 t sittenOver Easter, I have conducted some complex analyses of both micro- and macrotrends and concluded that Novo will hit price 1000 around mid-2031.·1 t sittenA good Easter lunch with friends, with lots of snaps beer & port wine, is always the ideal setup for preparing a sharp credible analysis. Novo definitely has the potential to become this year's winner on the sluggish C25. Going All Inn next week and buying 5 Novo shares. Done with gambling....
- ·4 t sittenInteresting to know how the weight loss percentage on the Wegovy pill is without fasting? If it without fasting matches Orforglipron, then the Wegovy pill has more possibilities.·2 t sittenYes, but I would still argue that if the one pill is almost 5% better, it will not be seen as a problem to take it in the morning. I myself take some medications that I can take in the morning, and it has just become a fixed routine, actually very good because then I don't have to wonder if I've taken the pill later in the day. So I feel completely sure that this will be the preferred pill, and will actually buy myself a bit more if we dip down towards 200.. Even though, isolatedly speaking, I shouldn't really have invested more, but this is a case where I see it as justifiable to invest a bit more than planned given that the stock has fallen so much.. I am actually a bit surprised by how short-sighted many stock traders are.. But these are just my thoughts, Have a continued good Easter, folks:-)
- ·5 t sittenNovo has in the first 3 months sold Wegovy pills for approx 1.5 billion kr. April will approx add 1 billion on top. Are there any expectations for the sales?·3 t sittenIs that your own assessment since Novo has not announced anything?·3 t sitten · MuokattuLast Friday, approximately 742,000 prescriptions were sold, and with all sales channels, the number is estimated to be approximately double. The 2 smallest doses cost almost 1,000 kr and approximately double for the 2 largest doses. So if the numbers are correct, then 1.5 billion in Q1 is underestimated. If 50/50 of the doses have been sold, the number is approximately 2.2 billion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
59 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenAnd to my Danish friends, in Norway we have a company called Kitron, it produces among other things components for the defense industry, among other things for Kongsberggruppen, I am absolutely sure that Kitron will at least double within one to two years as all of Europe/the world will now rearm the defense industry. But remember that such investments come from the public sector and often take some time, that's why I say one to two years..·22 min sittenDeeply overvalued. It is set to fall significantly.·18 min sittenPlease come over to the forum on stocks with great growth potential, I like to hear others' opinions when they are opposite of mine. As an investor, I must indeed look at all sides of a matter... Why do you think it's falling?
- ·2 t sittenThat's a huge piece of news from England. Strange that it doesn't create more positive sentiment. One million people are not just offered but directly encouraged by the public sector to take Wegovy. A price agreement with subsidies has been made. The group will presumably have it for life, and the group will only get bigger. That should be at least 20 billion annually into the coffers. Huge news. And it will undoubtedly set a precedent in other countries.·36 min sittenThis is probably somewhat in the middle. The case for Novo Nordisk is still strong in the long term, but much of the optimism surrounding obesity treatment has already been priced into the stock. NHS is positive, but hardly a gamechanger on its own. I have personally been badly burned by this stock; it is actually my biggest loss. Nevertheless, I am still holding it. In a 5 to 10-year perspective, I believe growth will come, but it won't be a straight line up. Competition, price pressure, and regulatory conditions will play a role along the way. Whether there's a buying opportunity now depends mostly on time horizon and patience. I have it as part of my core portfolio, but I have more faith in other stocks this current year.·32 min sittenSame here actually, have almost 50 percent loss, but can afford to stay invested for a long time if necessary, as long as there's hope for improvement, you know. Then I'll wait and see a bit, but if we drop down towards 200 then I'll add a bit more...thanks for the reply:-)
- ·3 t sittenOver Easter, I have conducted some complex analyses of both micro- and macrotrends and concluded that Novo will hit price 1000 around mid-2031.·1 t sittenA good Easter lunch with friends, with lots of snaps beer & port wine, is always the ideal setup for preparing a sharp credible analysis. Novo definitely has the potential to become this year's winner on the sluggish C25. Going All Inn next week and buying 5 Novo shares. Done with gambling....
- ·4 t sittenInteresting to know how the weight loss percentage on the Wegovy pill is without fasting? If it without fasting matches Orforglipron, then the Wegovy pill has more possibilities.·2 t sittenYes, but I would still argue that if the one pill is almost 5% better, it will not be seen as a problem to take it in the morning. I myself take some medications that I can take in the morning, and it has just become a fixed routine, actually very good because then I don't have to wonder if I've taken the pill later in the day. So I feel completely sure that this will be the preferred pill, and will actually buy myself a bit more if we dip down towards 200.. Even though, isolatedly speaking, I shouldn't really have invested more, but this is a case where I see it as justifiable to invest a bit more than planned given that the stock has fallen so much.. I am actually a bit surprised by how short-sighted many stock traders are.. But these are just my thoughts, Have a continued good Easter, folks:-)
- ·5 t sittenNovo has in the first 3 months sold Wegovy pills for approx 1.5 billion kr. April will approx add 1 billion on top. Are there any expectations for the sales?·3 t sittenIs that your own assessment since Novo has not announced anything?·3 t sitten · MuokattuLast Friday, approximately 742,000 prescriptions were sold, and with all sales channels, the number is estimated to be approximately double. The 2 smallest doses cost almost 1,000 kr and approximately double for the 2 largest doses. So if the numbers are correct, then 1.5 billion in Q1 is underestimated. If 50/50 of the doses have been sold, the number is approximately 2.2 billion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt